Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROTEA: Broncho-Vaxom in Preterm Infants for Respiratory Tract Infections and Wheeze
NCT05063149Phase 3Recruiting
- Sponsor
- Franciscus Gasthuis & Vlietland
- Start
- Mar 2022
- Primary completion
- Dec 2029
- Modality
- Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in respiratory tract infection (RTI) comparing Broncho-Vaxom treatment with Placebo (2 arms). Primary endpoint: Total number of physician diagnosed lower RTI and wheezing episodes at 1 year. Started Mar 2022; status: recruiting.
02
Drugs
OM-85
03
Conditions
respiratory tract infection (RTI)
Beyond the preview
Go deeper on NCT05063149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063149.